Related Experiment Videos
Heparin-induced thrombocytopenia. Pathogenesis, frequency, avoidance and management
1Hamilton Health Sciences Corporation and McMaster University, Ontario, Canada.
Drug Safety
|December 10, 1997
Summary
Heparin-induced thrombocytopenia (HIT) involves antibodies activating platelets and coagulation, increasing thrombosis risk. Warfarin-induced venous limb gangrene is a potential complication, but HIT may be preventable with low-molecular-weight heparins.
Area of Science:
- Hematology
- Immunology
- Pharmacology
Background:
- Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse drug reaction.
- HIT involves antibodies (HIT-IgG) targeting heparin and platelet factor 4, leading to platelet activation and coagulation.
- HIT is associated with a high risk of thrombotic complications.
Purpose of the Study:
- To explore the link between HIT, increased thrombin generation, and warfarin-induced venous limb gangrene.
- To discuss current and potential treatments for HIT.
- To investigate the potential prevention of HIT.
Main Methods:
- Review of existing literature on HIT pathophysiology, clinical manifestations, and treatment.
- Analysis of the role of antibody-mediated platelet activation and coagulation cascade.
- Comparison of HIT incidence with unfractionated heparin versus low-molecular-weight heparins.
Main Results:
- HIT involves both platelet activation and increased thrombin generation.
- Warfarin-induced venous limb gangrene may be a complication of HIT due to acquired protein C deficiency.
- Low-molecular-weight heparins appear to reduce the frequency of HIT, thrombosis, and antibody development compared to unfractionated heparin.
Conclusions:
- HIT is a complex condition with significant thrombotic risks.
- Effective treatments focus on inhibiting thrombin generation.
- Switching to low-molecular-weight heparins may be a preventative strategy for HIT and its complications.